PREvention of bloodstream infections with Vancomycin resistant ENTerococci - Case-Control Study

PREvention of bloodstream infections with Vancomycin resistant ENTerococci - Case-Control Study - PREVENT Case-Control Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00040325

Enrollment

555

Registered

2026-07-15

Start date

2026-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bloodstream infection by Vancomycin-resistant enterococci

Interventions

Group 1: Hospitalized patients with bloodstream infections caused by vancomycin-resistant enterococci (VRE) (detected via blood culture) during 2023–2024 Group 2: Hospitalized patients with documented

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Cases: Blood culture-confirmed VRE bloodstream infection Controls: Detection of VRE in a culture-positive rectal/anal swab

Exclusion criteria

Exclusion criteria: Polymicrobial bloodstream infection (VRE + VSE/linezolid-resistant enterococci/other non-enterococcal species) Cases: No documented targeted antimicrobial therapy Controls: Prior blood culture-confirmed VRE bacteremia

Design outcomes

Primary

Measure	Time frame
Occurrence of a VRE bloodstream infection during hospitalization. Data collection via retrospective, anonymized chart review. The aim of the analyses is to investigate factors that might influence the occurrence of a VRE bloodstream infection.	—

Countries

Germany

Contacts

Public ContactKathrin Ungethüm

Universitätsklinikum Würzburg

prevent@ukw.de+49 931 201 47342

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026